No evidence for evolution of protease inhibitor resistance from standard genotyping, after three years of treatment with darunavir/ritonavir, with or without nucleoside analogues

AIDS Research and Human Retroviruses

Volumn 28, Issue 10, 2012, Pages 1167-1169

  Pulido, Federico ^a   Arribas, Jose ^b   Hill, Andrew ^c   Moecklinghoff, Christiane ^d  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; DARUNAVIR PLUS RITONAVIR; FOSAMPRENAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR; LOPINAVIR; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TIPRANAVIR; VIRUS RNA;

GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MONOTHERAPY; PHENOTYPE; PRIORITY JOURNAL; VIREMIA; VIRUS RESISTANCE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV PROTEASE INHIBITORS; HUMANS; NUCLEOSIDES; RITONAVIR; RNA, VIRAL; SULFONAMIDES; TIME FACTORS; VIRAL LOAD;

EID: 84866649895     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0256     Document Type: Letter

References (15)

1. Gupta R, Hill A, Sawyer A, et al.: Emergence of drug resistance in HIV Type 1-infected patients after receipt of first-line highly active antiretroviral therapy: A systematic review of clinical trials. Clin Infect Dis 2008;47: 712-722.
2. The UK Collaborative Group on HIV Drug Resistance and UK CHIC Study Group: Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 2005;19:487-494.
3. Von Wyl V, Yerly S, Boni J, Burgisser P, Klimkait T, Battegay M, et al.: Swiss HIV Cohort Study. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: A comparison of different regimen types. Arch Intern Med 2007;167:1782-1790.
4. Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, and Boucher CA: HIV monotherapy with ritonavir-boosted protease inhibitors: A systematic review. AIDS 2009;23:279-291.
5. Battegay M and Bucher H: Antiretroviral monotherapy: Should we abandon the principles of successful anti-retroviral therapy? AIDS 2010;24(7):1057-1059.
6. Arribas J, Horban A, Gerstoft J, et al.: The MONET trial: Darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS 2010; 24(2):223-230.
7. Clumeck N, Rieger A, Banhegyi D, Schmidt W, Hill A, van Delft Y, et al.: 96 week results from the MONET trial: A randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline. J Antimicrob Chemother 2011; 66(8):1878-1885.
8. Hirsch M, Gunthard H, Schapiro J, et al.: Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2008;47:266-285.
9. Stanford University HIV Drug resistance database: A cu-rated public database designed to represent, store and analyse different forms of data underlying HIV drug resistance. Available online at http://hivdb.stanford.edu/ index.html. Accessed January 2010.
10. Pulido F, Arribas JR, Hill A, Van Delft Y, and Moecklinghoff C: Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy. An-tivir Ther 2011;16(1):59-65.
11. Valentin M, Duvivier C, Lambert S, Flandre P, Cabie P, Molina J, et al.: Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression in the MONOI-ANRS 136 trial: Results at week 96. Presented at the Conference on Retroviruses and Opportunistic Infections (CROI), Boston, MA, February 2011 [Abstr. 534].
12. Pulido F, Perez-Valero I, Delgado R, Arranz A, Pasquau J, Portilla J, et al.: Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. Antivir Ther 2009;14:195-201.
13. Meynard J, Buteloup V, Landman R, Bonnard P, Baillat V, Cabie A, et al.: Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: The Kalesolo trial. J Antmicrob Chemother 2010;65:2436-2444.
14. Prosperi M, Mackie N, Di Giambenedetto S, Zazzi M, Camacho R, Fanti R, et al.: Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multi-center cohort study. J Antimicrob Chemother 2011;66(8): 1886-1896.
15. McKinnon J, Delgado R, Pulido F, Shao W, Arribas J, and Mellors J: Single genome sequencing of HIV-1 gag and protease inhibitor resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapy. Antivir Ther 2011;16(5):725-732.